Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies
Open Access
- 1 March 1990
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 61 (3) , 471-474
- https://doi.org/10.1038/bjc.1990.104
Abstract
Natural killer (NK) cell activity and lymphokine activated killer (LAK) cell cytotoxicity were measured in patients receiving recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) for treatment of progressing metastatic melanoma. NK activity was increased in 23 of 26 patients and LAK activity induced in 13 of 26 patients. However, levels of cytotoxicity in the present study were not significantly greater than a previous study using rIL-2 alone. LAK cell precursors demonstrated by in vitro incubation of pretreatment lymphocytes with IL-2 and subsequent cytotoxicity were no different in the patients compared to normal controls. Analysis of cell surface phenotypes failed to reveal any significant changes in the cell populations examined, including IL-2R and Leu 19. Although five patients had tumour response, one being complete, there was no correlation with the immunological parameters examined.Keywords
This publication has 22 references indexed in Scilit:
- Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II studyBritish Journal of Cancer, 1989
- EFFECTS OF SYSTEMIC RECOMBINANT INTERLEUKIN-2 ON NATURAL-KILLER AND LYMPHOKINE ACTIVATED KILLER ACTIVITY OF HUMAN-TUMOR INFILTRATING LYMPHOCYTES1988
- Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512)European Journal of Cancer and Clinical Oncology, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Surface markers of human lymphokine-activated killer cells and their precursors. Analysis at the population and clonal levelInternational Journal of Cancer, 1987
- THERAPEUTIC AND PHARMACOKINETIC RELATIONSHIPS OF FLAVONE ACETIC-ACID - AN AGENT WITH ACTIVITY AGAINST SOLID TUMORS1986
- Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.The Journal of Immunology, 1985
- Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.The Journal of Immunology, 1985
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984